Intervention Review

You have free access to this content

Beclometasone for chronic obstructive pulmonary disease

  1. Daan A De Coster1,*,
  2. Melvyn Jones2,
  3. Nikita Thakrar3

Editorial Group: Cochrane Airways Group

Published Online: 9 OCT 2013

Assessed as up-to-date: 6 FEB 2013

DOI: 10.1002/14651858.CD009769.pub2


How to Cite

De Coster DA, Jones M, Thakrar N. Beclometasone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD009769. DOI: 10.1002/14651858.CD009769.pub2.

Author Information

  1. 1

    University College London, Upper 3rd Floor, UCL Medical School (Royal Free Campus), Department of Primary Care and Population Health, London, UK

  2. 2

    UCL, Department of Primary Care and Population Health, Division of Population Health, Faculty of Population Health Sciences, London, UK

  3. 3

    UCL, Department of Primary Care and Population Health, London, UK

*Daan A De Coster, Department of Primary Care and Population Health, University College London, Upper 3rd Floor, UCL Medical School (Royal Free Campus), Rowland Hill Street, London, NW3 2PF, UK. d.coster@ucl.ac.uk. decosterdaan@googlemail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 9 OCT 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Calverley 2010 {published data only}
  • Calverley PM, Kuna P, Monsó E, Costantini M, Petruzzelli S, Sergio F, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine 2010;104(12):1858-68. [DOI: 10.1016/j.rmed.2010.09.008; : http://clinicaltrials.gov/show/NCT00476099; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/20965712]
Derenne 1995 {published and unpublished data}
  • Derenne JP. Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study. American Journal of Respiratory and Critical Care Medicine 1995;151:A463.
  • van Grunsven PM. Chapter 8: Beneficial clinical effects of a two-year treatment with inhaled beclomethasone dipropionate 1500 µg daily in moderate to severe chronic obstructive pulmonary disease—a multicenter randomized placebo-controlled trial. Asthma and Chronic Obstructive Pulmonary Disease (COPD)—Aspects of Treatment With Inhaled Corticosteroids of Patients With Mild Signs or a Clinical Diagnosis [Dissertation]. Radboud Repository, Radboud University Nijmegen, 1999. [URL: http://hdl.handle.net/2066/19002]
Weir 1999 {published and unpublished data}

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Boothman-Burrell 1997 {published data only}
  • Boothman-Burrell D, Delany SG, Flannery EM, Hancox RJ, Taylor DR. The efficacy of inhaled corticosteroids in the management of non asthmatic chronic airflow obstruction. New Zealand Medical Journal October 1997;110(1053):370-3. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/9364183]
Dinc 2001 {published data only}
  • Dinc M,  Tchugunova Y,  Dinc S,  Cinarli B,  Atasever T,  Oz M. Decreased osteocalcin levels in patients with chronic obstructive pulmonary disease using long-term inhaled beclomethasone dipropionate. Metabolism: Clinical and Experimental 2001;50(11):1336-9. [DOI: 10.1053/meta.2001.27231; : http://www.sciencedirect.com/science/article/pii/S0026049501997914; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/11699053]
John 2005 {published and unpublished data}
  • John M, Bosse S, Oltmanns U, Schumacher A, Witt C. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respiratory Medicine 2005;99(11):1418-24. [DOI: 10.1016/j.rmed.2005.03.034; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/15894479]
  • John M, Bosse S, Schumacher A, Oltmanns U, Witt C. Effect of inhaled beclomethasone HFA 134 (QVAR/Ventolair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego. [A43] [Poster: F43].
Miravitlles 2002 {published data only}
  • Miravitlles M, Alvarez Sala JL, Lamarca R, Ferrer M, Masa F, Verea H. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Quality of Life Research 2002;11(4):329-38.
Ouyang 1998 {published data only}
  • Ouyang R, Yin B. Clinical study of inhaled corticosteroid in non-asthmatic chronic obstructive pulmonary disease. Chung-Hua Chieh Ho Ho Hu Hsi Tsa Chih 1998;21(8):497-9. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/11360524]
Shmelev 2006 {published and unpublished data}
  • Shmelev EI, Kunicina YL. Comparison of fenspiride with beclomethasone as adjunctive anti-inflammatory treatment in patients with chronic obstructive pulmonary disease. Clinical Drug Investigation 2006;26(3):151-9. [: http://adisonline.com/druginvestigation/Abstract/2006/26030/Comparison_of_Fenspiride_with_Beclomethasone_as.5.aspx]
Struijs 1997 {published data only}
  • Struijs A, Mulder H. The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide. Netherlands Journal of Medicine 1997;50(6):233-7. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/9232087]
Thompson 1992 {published data only}
  • Thompson AB, Mueller MB, Heires AJ, Bohling TL, Daughton D, Yancey SW, et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. American Review of Respiratory Disease 1992;146(2):389-95. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/1489129]
Tzani 2011 {published data only}
  • Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini EM, et al. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2011;6:503-9. [DOI: 10.2147/COPD.S23746; : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206766/]
  • Tzani P, Crisafulli E, Nicolini G, Clini E, Aiello M, Chetta A, et al. Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD [Abstract]. European Respiratory Society 20th Annual Congress; 2010 September 18-22; Barcelona.
van Schayck 1995 {published data only}
  • van Schayck CP, Dompeling E, Rutten MP, Folgering H, van den Boom G, van Weel C. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995;107(5):1199-205. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/7750306]
Weir 1990 {published data only}
  • Weir DC, Gove RI, Robertson AS, Burge PS. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax 1990;45(2):112-17. [: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC462320/; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/2180105]
Weir 1993 {published data only}
  • Weir DC, Burge PS. Effects of high dose inhaled beclomethasone dipropionate 750 μg and 1500 μg twice daily and 40 mg oral prednisolone on lung function, symptoms and bronchial hyperresponsiveness in patients with non-asthmatic airflow obstruction. Thorax 1993;48(4):309-16. [: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC464423/; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/8511727]

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Vengerov 1998 {published and unpublished data}
  • Vengerov B. Effectiveness of long-term treatment with inhaled corticosteroids in metal workers with COPD. European Respiratory Journal Supplement 1998;12(Suppl 28):413S.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Wedzicha (FORWARD) 2013 {published data only}
  • Singh D, Kampschulte J,  Wedzicha JA,  Jones PW,  Cohuet G,  Corradi M,  et al. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. European Respiratory Journal 2013;41(1):12-7. [DOI: 10.1183/09031936.00207611; PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/22653766]
  • Wedzicha WA. BDP/FF versus formoterol fumarate (FF) in patients with severe COPD (lung function and exacerbation rate). http://clinicaltrials.gov/ct2/show/NCT00929851 (accessed 26 June 2013).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Adams 2007
Agarwal 2010
  • Agarwal R, Agarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest 2010;137(2):318-25.
Anon. 2010
  • Anon. Preventing exacerbations in COPD. Drug and Therapeutics Bulletin 2010;48(7):74-7.
ATS 1987
  • American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. American Review of Respiratory Disease 1987;136:225-43. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/3605835]
ATS/ERS 2004
  • American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients With COPD. 1.2. New York: American Thoracic Society, 2004.
Bradley-Drummond 2008
  • Bradley-Drummond M, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(20):2407-16.
Britton 2003
Brocklebank 2001a
  • Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technology Assessment 2001;5(26):1-149. [: http://www.ncbi.nlm.nih.gov/pubmed/11701099; PUBMED: 11701099]
Brocklebank 2001b
  • Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. British Medical Journal 2001;323(7318):896-900.
Brown 1972
BTS 1997
  • British Thoracic Society Standards of Care Committee. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 5):S1-8. [: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1765890/; PMCID: PMC1765890]
Buscemi 2006
  • Buscemi N, Hartling L, Vandermeer B, Tjosvold L, Klassen TP. Single data extraction generated more errors than double data extraction in systematic reviews. Journal of Clinical Epidemiology 2006;59:697-703.
CAG 2008
  • Cochrane Airways Group. Developing a search strategy for an Airways Group systematic review. http://airways.cochrane.org/authors (accessed 2 January 2012).
Cazzola 2008
  • Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. American Thoracic Society, European Respiratory Society Task Force on Outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal 2008;31(2):416-69. [DOI: 10.1183/09031936.00099306; PUBMED: 18238951]
Celli 2004
  • Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New England Journal of Medicine 2004;350(10):1005-12. [PUBMED: www.ncbi.nlm.nih.gov/pubmed/14999112]
Clark 1997
Dolovich 2005
  • Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. American College of Chest Physicians, American College of Asthma, Allergy, Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127(1):335-71. [DOI: 10.1378/chest.127.1.335; : http://www.ncbi.nlm.nih.gov/pubmed/15654001; PUBMED: 15654001]
Fabbri 1993
  • Fabbri L, Burge PS, Croonenborgh L, Warlies F, Weeke B, Ciaccia A, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993;48(8):817-23.
Fletcher 1964
  • Fletcher CM, Jones NL, Burrows B, Niden AH. American emphysema and British bronchitis: a standardized comparative study. American Review of Respiratory Disease 1964;90:1-13.
Gartlehner 2006
  • Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Annals of Family Medicine 2006;4(3):253-62.
GOLD 2010
  • Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/. Barcelona: Global Initiative for Chronic Obstructive Lung Disease, Inc., (accessed 12 January 2011).
GOLD 2013
  • Gold Science Committee. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.org/ (accessed 7 October 2013).
Guyatt 1987
Higgins 2011
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
Ivancsó 2013
  • Ivancsó I, Böcskei R, Müller V, Tamási L. Extrafine inhaled corticosteroid therapy in the control of asthma. Journal of Asthma and Allergy 2013;6:69-80. [DOI: 10.2147/JAA.S25415; : http://www.ncbi.nlm.nih.gov/pubmed/23776339; PUBMED: 23776339]
Izquierdo 2003
  • Izquierdo JL. Chronic obstructive lung disease: corticosteroids [Corticoides en la EPOC]. Archivos de Bronconeumologia 2003;39(Suppl 3):25-7.
Jones 2002
  • Jones A, Fay JK, Burr MI, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003537]
Kelly 2009
Kemp 2010
  • Kemp L, Haughney J, Barnes N, Sims E, von Ziegenweidt J, Hillyer EV, et al. Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: a real world observational study. ClinicoEconomics and Outcomes Research 2010;2:75-85. [: http://www.ncbi.nlm.nih.gov/pubmed/21935316/; PUBMED: 21935316]
Kunka 2000
  • Kunka R, Andrews S, Pimazzoni M, Callejas S, Ziviani L, Squassante L, et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respiratory Medicine 2000;94(Suppl B):S10-6. [PUBMED: 10919680 ]
Leach 1998
Lipworth 1999
Loke 2010
  • Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. European Respiratory Journal 2010;35(5):1003-21.
Longest 2012
  • Longest PW, Tian G, Walenga RL, Hindle M. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Pharmaceutical Research 2012;29(6):1670-88. [DOI: 10.1007/s11095-012-0691-y; : http://www.ncbi.nlm.nih.gov/pubmed/22290350; PUBMED: 22290350]
Lucas 2008
  • Lucas AEM, Smeenk FWJM, Smeele IJ, Van Schayck CP. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients: an exploratory study. Family Practice 2008;25(2):86-91.
Mahler 1988
Martin 2002
  • Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. American Journal of Respiratory Care Medicine 2002;165(10):1377-83.
MHRA 2006
  • Medicines and Healthcare products Regulatory Agency (MHRA). CLENIL® MODULITE® 50 micrograms peractuation pressurised inhalation solution (beclometasone dipropionate) PL 08829/0133 Public Assessment Report. www.mhra.gov.uk/home/groups/l-unit1/documents/.../con014210.pdf‎ (accessed 26 June 2013).
Miller 2005
Moher 2009
Nannini 2007
  • Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3]
Nannini 2012
  • Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2; URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006829.pub2/abstract]
NCGC 2010
  • National Collaborating Centre for Acute and Chronic Conditions. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care, 2010. http://www.nice.org.uk/guidance/CG101 (accessed 7/10/13).
NPC 2008
  • National Prescribing Centre. COPD: data focused commentary. http://www.npc.nhs.uk/therapeutics/respiratory/copd/data.php (accessed 1 February 2012).
Papi 2007
  • Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM, Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. European Respiratory Journal 2007;29(4):682-9. [DOI: 10.1183/09031936.00095906; : http://www.ncbi.nlm.nih.gov/pubmed/17107988; PUBMED: 17107988]
Price 2011
  • Price D, Haughney J, Sims E, Ali M, von Ziegenweidt J, Hillyer EV, et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. Journal of Asthma and Allergy 2011;4:37-47. [DOI: 10.2147/JAA.S17709; : http://www.ncbi.nlm.nih.gov/pubmed/21698214; PUBMED: 21698214]
Quanjer 1983
  • Quanjer PH. Standardized lung function testing. Bulletin Europeen de Physiopathologie Respiratoire 1983;19(Suppl 5):7-10.
Ram 2002
  • Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD003902]
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Richy 2003
  • Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morri H, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporosis International 2003;14(3):179-90.
Rodrigo 2009
  • Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136(4):1029-38.
Selroos 2009
  • Selroos O, Borgstrom L, Ingelf J. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Therapeutic Advances in Respiratory Disease 2009;3(2):81-91.
Sin 2009
  • Sin DA, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:7129.
Spencer 2011
  • Spencer S, Evans DJ, Karner C, Cates CJ. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD007033.pub3]
Suissa 2009
TORCH 2007
  • Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007;356(8):775-89.
van Grunsven 1999
  • van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54(1):7-14. [PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/10343624]
Wales 1999
  • Wales D, Makker H, Kane J, McDowell P, O'Driscoll BR. Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest 1999;115(5):1278-84.
Welsh 2010
  • Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD007891.pub2]
WHO 2008
  • World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: WHO Press, 2008.
Yang 2007
Yang 2012